Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Sarcoma 1

Conditions

Multiple Myeloma 809Neoplasms, Plasma Cell 111Recurrence 109Immunoglobulin Light-chain Amyloidosis 50Neoplasms 33Amyloidosis 21Smoldering Multiple Myeloma 15Renal Insufficiency 13Paraproteinemias 12Lymphoma, Non-Hodgkin 12Hematologic Diseases 11Leukemia, Plasma Cell 10Lymphoma 9Plasmacytoma 8Leukemia, Myeloid, Acute 7Hematologic Neoplasms 7Disease 6Blood Protein Disorders 6Lymphoma, Large B-Cell, Diffuse 5Leukemia, Lymphocytic, Chronic, B-Cell 5Leukemia 5Hodgkin Disease 5Neoplasm, Residual 4Nausea 4Myelodysplastic Syndromes 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Disease Progression 4Chromosome 17 deletion 4

Interventions

Dexamethasone 3Bortezomib 3pomalidomide 2isatuximab 2trametinib 1ricolinostat 1ficlatuzumab 1dabrafenib 1cobimetinib 1Vorinostat 1Vemurafenib 1Ranitidine 1Lenalidomide 1Erlotinib Hydrochloride 1Diphenhydramine 1Cyclophosphamide 1Acetaminophen 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × Dexamethasone × Plasma cell × Clear all
NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1/2 Terminated
103 enrolled 21 charts
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Hellenic Society of Hematology

Phase 2 Unknown
51 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡